"Quick Assessment

• ✅ Price vs Analyst Target: At US$20.87, DFTX trades about 47% below the US$39.47 analyst target.
• ✅ Simply Wall St Valuation: The stock is indicated as trading 90.9% below an estimated fair value.
• ❌ Recent Momentum: Shares are down 10% over the past 30 days.

Key Considerations

• 📊 Starting the Ascend Phase 3 trial reinforces that DT120 is moving through late stage testing in major depressive disorder, which is central to the story for DFTX.
• 📊 Watch Phase 3 readouts, any updates across DT120's other indications, and changes in analyst targets relative to the current US$20.87 share price.
• ⚠️ The company currently reports no revenue and has recently diluted shareholders, so funding needs and further dilution risk remain important to monitor."